SURMODICS ($SRDX) posted quarterly earnings results on Friday, August 8th. The company reported earnings of $0.06 per share, beating estimates of -$0.19 by $0.25. The company also reported revenue of $29,570,000, beating estimates of $28,616,100 by $953,900.
You can see Quiver Quantitative's $SRDX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SURMODICS Hedge Fund Activity
We have seen 62 institutional investors add shares of SURMODICS stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- READYSTATE ASSET MANAGEMENT LP added 433,612 shares (+inf%) to their portfolio in Q2 2025, for an estimated $12,882,612
- SOLEUS CAPITAL MANAGEMENT, L.P. added 395,000 shares (+100.2%) to their portfolio in Q1 2025, for an estimated $12,059,350
- TRIGRAN INVESTMENTS, INC. removed 368,215 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $11,241,603
- BERYL CAPITAL MANAGEMENT LLC removed 237,584 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $7,253,439
- GARDNER LEWIS ASSET MANAGEMENT L P removed 201,221 shares (-76.5%) from their portfolio in Q1 2025, for an estimated $6,143,277
- BARDIN HILL MANAGEMENT PARTNERS LP removed 187,869 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $5,735,640
- HUDSON BAY CAPITAL MANAGEMENT LP added 164,969 shares (+55.0%) to their portfolio in Q1 2025, for an estimated $5,036,503
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SURMODICS Analyst Ratings
Wall Street analysts have issued reports on $SRDX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 03/07/2025
To track analyst ratings and price targets for SURMODICS, check out Quiver Quantitative's $SRDX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
